nach oben

Erschienen in:

15.11.2021 | Original Article

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

verfasst von: Eun Young Kang, Joshua Millstein, Gordana Popovic, Nicola S. Meagher, Adelyn Bolithon, Aline Talhouk, Derek S. Chiu, Michael S. Anglesio, Betty Leung, Katrina Tang, Neil Lambie, Marina Pavanello, Annalyn Da-anoy, Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Christiani Bisinotto, Jesus Garcia-Donas, Sergio Ruiz-Llorente, Monica Yagüe-Fernandez, Robert P. Edwards, Esther Elishaev, Alexander Olawaiye, Sarah Taylor, Beyhan Ataseven, Andreas du Bois, Philipp Harter, Jenny Lester, Claus K. Høgdall, Sebastian M. Armasu, Yajue Huang, Robert A. Vierkant, Chen Wang, Stacey J. Winham, Sabine Heublein, Felix K. F. Kommoss, Daniel W. Cramer, Naoko Sasamoto, Lilian van-Wagensveld, Maria Lycke, Constantina Mateoiu, Janine Joseph, Malcolm C. Pike, Kunle Odunsi, Chiu-Chen Tseng, Celeste L. Pearce, Sanela Bilic, Thomas P. Conrads, Arndt Hartmann, Alexander Hein, Michael E. Jones, Yee Leung, Matthias W. Beckmann, Matthias Ruebner, Minouk J. Schoemaker, Kathryn L. Terry, Mona A. El-Bahrawy, Penny Coulson, John L. Etter, Katherine LaVigne-Mager, Juergen Andress, Marcel Grube, Anna Fischer, Nina Neudeck, Greg Robertson, Rhonda Farrell, Ellen Barlow, Carmel Quinn, Anusha Hettiaratchi, Yovanni Casablanca, Ramona Erber, Colin J. R. Stewart, Adeline Tan, Yu Yu, Jessica Boros, Alison H. Brand, Paul R. Harnett, Catherine J. Kennedy, Nikilyn Nevins, Terry Morgan, Peter A. Fasching, Ignace Vergote, Anthony J. Swerdlow, Francisco J. Candido dos Reis, G. Larry Maxwell, Susan L. Neuhausen, Arantzazu Barquin-Garcia, Francesmary Modugno, Kirsten B. Moysich, Philip J. Crowe, Akira Hirasawa, Florian Heitz, Beth Y. Karlan, Ellen L. Goode, Peter Sinn, Hugo M. Horlings, Estrid Høgdall, Karin Sundfeldt, Stefan Kommoss, Annette Staebler, Anna H. Wu, Paul A. Cohen, Anna DeFazio, Cheng-Han Lee, Helen Steed, Nhu D. Le, Simon A. Gayther, Kate Lawrenson, Paul D. P. Pharoah, Gottfried Konecny, Linda S. Cook, Susan J. Ramus, Linda E. Kelemen, Martin Köbel

Erschienen in: Virchows Archiv | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms that generally respond well to platinum/taxane chemotherapy. We recently identified minichromosome maintenance complex component 3 (MCM3), which is involved in the initiation of DNA replication and proliferation, as a favorable prognostic marker in HGSC. Our objective was to further validate whether MCM3 mRNA expression and possibly MCM3 protein levels are associated with survival in patients with HGSC. MCM3 mRNA expression was measured using NanoString expression profiling on formalin-fixed and paraffin-embedded tissue (N = 2355 HGSC) and MCM3 protein expression was assessed by immunohistochemistry (N = 522 HGSC) and compared with Ki-67. Kaplan–Meier curves and the Cox proportional hazards model were used to estimate associations with survival. Among chemotherapy-naïve HGSC, higher MCM3 mRNA expression (one standard deviation increase in the score) was associated with longer overall survival (HR = 0.87, 95% CI 0.81–0.92, p < 0.0001, N = 1840) in multivariable analysis. MCM3 mRNA expression was highest in the HGSC C5.PRO molecular subtype, although no interaction was observed between MCM3, survival and molecular subtypes. MCM3 and Ki-67 protein levels were significantly lower after exposure to neoadjuvant chemotherapy compared to chemotherapy-naïve tumors: 37.0% versus 46.4% and 22.9% versus 34.2%, respectively. Among chemotherapy-naïve HGSC, high MCM3 protein levels were also associated with significantly longer disease-specific survival (HR = 0.52, 95% CI 0.36–0.74, p = 0.0003, N = 392) compared to cases with low MCM3 protein levels in multivariable analysis. MCM3 immunohistochemistry is a promising surrogate marker of proliferation in HGSC.

Nur mit Berechtigung zugänglich

Peres LC, Cushing-Haugen KL, Kobel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA (2019) Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst 111:60–68. https://doi.org/10.1093/jnci/djy071CrossRefPubMed

Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, Leong SCY, Liu G, Johnson D, Chen B, Group A, Alsop J, Banerjee SN, Behrens S, Bodelon C, Brand AH, Brinton L, Carney ME, Chiew YE, Cushing-Haugen KL, Cybulski C, Ennis D, Fereday S, Fortner RT, García-Donas J, Gentry-Maharaj A, Glasspool R, Goranova T, Greene CS, Haluska P, Harris HR, Hendley J, Hernandez BY, Herpel E, Jimenez-Linan M, Karpinskyj C, Kaufmann SH, Keeney GL, Kennedy CJ, Köbel M, Koziak JM, Larson MC, Lester J, Lewsley LA, Lissowska J, Lubiński J, Luk H, Macintyre G, Mahner S, McNeish IA, Menkiszak J, Nevins N, Osorio A, Oszurek O, Palacios J, Hinsley S, Pearce CL, Pike MC, Piskorz AM, Ray-Coquard I, Rhenius V, Rodriguez-Antona C, Sharma R, Sherman ME, De Silva D, Singh N, Sinn P, Slamon D, Song H, Steed H, Stronach EA, Thompson PJ, Tołoczko A, Trabert B, Traficante N, Tseng CC, Widschwendter M, Wilkens LR, Winham SJ, Winterhoff B, Beeghly-Fadiel A, Benitez J, Berchuck A, Brenton JD, Brown R, Chang-Claude J, Chenevix-Trench G, deFazio A, Fasching PA, García MJ, Gayther SA, Goodman MT, Gronwald J, Henderson MJ, Karlan BY, Kelemen LE, Menon U, Orsulic S, Pharoah PDP, Wentzensen N, Wu AH, Schildkraut JM, Rossing MA, Konecny GE, Huntsman DG, Huang RY, Goode EL, Ramus SJ, Doherty JA, Bowtell DD, Anglesio MS (2020) Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin Cancer Res 26:5411–5423. https://doi.org/10.1158/1078-0432.Ccr-20-0103CrossRefPubMedPubMedCentral

Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D’Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382–390. https://doi.org/10.1001/jama.2012.20CrossRefPubMedPubMedCentral

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PDP, Goode EL, Huntsman DG, Ramus SJ (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14:853–862. https://doi.org/10.1016/s1470-2045(13)70253-5CrossRefPubMedPubMedCentral

Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Kobel M (2020) Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. J Pathol Clin Res 6:252–262. https://doi.org/10.1002/cjp2.168CrossRefPubMedPubMedCentral

Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, Group A, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Kobel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva De Silva D, Ramon YCT, Garcia-Donas J, Hernando Polo S, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubinski J, Oszurek O, Toloczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, Garcia MJ, Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol 31:1240–1250. https://doi.org/10.1016/j.annonc.2020.05.019CrossRefPubMed

Forsburg SL (2004) Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev 68:109–131. https://doi.org/10.1128/mmbr.68.1.109-131.2004CrossRefPubMedPubMedCentral

Zhao Y, Wang Y, Zhu F, Zhang J, Ma X, Zhang D (2020) Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients. Clin Exp Med 20:249–259. https://doi.org/10.1007/s10238-019-00604-4CrossRefPubMed

Zhou H, Xiong Y, Zhang G, Liu Z, Li L, Hou S, Zhou T (2020) Elevated expression of minichromosome maintenance 3 indicates poor outcomes and promotes G1/S cell cycle progression, proliferation, migration and invasion in colorectal cancer. Biosci Rep 40. https://doi.org/10.1042/bsr20201503

10.

Valverde LF, de Freitas RD, Pereira TA, de Resende MF, Agra IMG, Dos Santos JN, Dos Reis MG, Sales CBS, Gurgel Rocha CA (2018) MCM3: a novel proliferation marker in oral squamous cell carcinoma. Appl Immunohistochem Mol Morphol 26:120–125. https://doi.org/10.1097/pai.0000000000000397CrossRefPubMed

11.

Ehlén Å, Nodin B, Rexhepaj E, Brändstedt J, Uhlén M, Alvarado-Kristensson M, Pontén F, Brennan DJ, Jirström K (2011) RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol 4:212–221. https://doi.org/10.1593/tlo.11106CrossRefPubMedPubMedCentral

12.

Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, Dziegiel P (2013) Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res 33:5375–5383PubMed

13.

Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D, Silva EG (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174. https://doi.org/10.1097/PAS.0b013e31803199b0CrossRefPubMed

14.

Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232. https://doi.org/10.1371/journal.pmed.0050232CrossRefPubMedPubMedCentral

15.

Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, Wu X (2016) A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep 6:25408. https://doi.org/10.1038/srep25408CrossRefPubMedPubMedCentral

16.

Chen M, Yao S, Cao Q, Xia M, Liu J, He M (2017) The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients. Oncotarget 8:107877–107885. https://doi.org/10.18632/oncotarget.14112CrossRefPubMed

17.

Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski V, Gares V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Kobel M, Harnett P, Nelson BH, Bowtell DDL, deFazio A, Nadia Traficante ftAOCSG (2018) Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer. Clin Cancer Res 24:569–580. https://doi.org/10.1158/1078-0432.CCR-17-1621CrossRefPubMed

18.

Kobel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, Le ND, Cook LS (2019) Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions Int. J Gynecol Pathol 38:353–362. https://doi.org/10.1097/pgp.0000000000000530CrossRef

19.

Mackenzie R, Talhouk A, Eshragh S, Lau S, Cheung D, Chow C, Le N, Cook LS, Wilkinson N, McDermott J, Singh N, Kommoss F, Pfisterer J, Huntsman DG, Kobel M, Kommoss S, Gilks CB, Anglesio MS (2015) Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. Am J Surg Pathol 39:1548–1557. https://doi.org/10.1097/pas.0000000000000476CrossRefPubMedPubMedCentral

20.

Talhouk A, Kommoss S, Mackenzie R, Cheung M, Leung S, Chiu DS, Kalloger SE, Huntsman DG, Chen S, Intermaggio M, Gronwald J, Chan FC, Ramus SJ, Steidl C, Scott DW, Anglesio MS (2016) Single-patient molecular testing with NanoString nCounter data using a reference-based strategy for batch effect correction. PLoS ONE 11:e0153844. https://doi.org/10.1371/journal.pone.0153844CrossRefPubMedPubMedCentral

21.

Kobel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD (2016) Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2:247–258. https://doi.org/10.1002/cjp2.53CrossRefPubMedPubMedCentral

22.

Hunt AL, Bateman NW, Barakat W, Makohon-Moore S, Hood BL, Conrads KA, Zhou M, Calvert V, Pierobon M, Loffredo J, Litzi TJ, Oliver J, Mitchell D, Gist G, Rojas C, Blanton B, Robinson EL, Odunsi K, Sood AK, Casablanca Y, Darcy KM, Shriver CD, Petricoin EF, Rao UNM, Maxwell GL, Conrads TP (2021) Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. iScience 24:102757. https://doi.org/10.1016/j.isci.2021.102757CrossRefPubMedPubMedCentral

23.

Liu Y, Beyer A, Aebersold R (2016) On the dependency of cellular protein levels on mRNA abundance. Cell 165:535–550. https://doi.org/10.1016/j.cell.2016.03.014CrossRefPubMed

24.

Jensen K, Krusenstjerna-Hafstrøm R, Lohse J, Petersen KH, Derand H (2017) A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. Mod Pathol 30:180–193. https://doi.org/10.1038/modpathol.2016.176CrossRefPubMed

25.

Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL (2021) Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. NPJ Precis Oncol 5:45. https://doi.org/10.1038/s41698-021-00184-1CrossRefPubMedPubMedCentral

26.

Bromley AB, Altman AD, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Han G, Kobel M (2012) Architectural patterns of ovarian/pelvic high-grade serous carcinoma. Int J Gynecol Pathol 31:397–404. https://doi.org/10.1097/PGP.0b013e31824c2372CrossRefPubMed

27.

Miller K, Price JH, Dobbs SP, McClelland RH, Kennedy K, McCluggage WG (2008) An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol 61:652–657. https://doi.org/10.1136/jcp.2007.053793CrossRefPubMed

28.

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB, Singh N (2017) A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. Histopathology 71:736–742. https://doi.org/10.1111/his.13272CrossRefPubMed

29.

Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF (2020) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa201CrossRefPubMedPubMedCentral

30.

Jaafari-Ashkavandi Z, Mehranmehr F, Roosta E (2019) MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma. J Oral Biol Craniofac Res 9:47–50. https://doi.org/10.1016/j.jobcr.2018.09.003CrossRefPubMed

31.

Lameira AG, Pontes FS, Guimarães DM, Alves AC, de Jesus AS, Pontes HA, dos Santos Pinto D Jr (2014) MCM3 could be a better marker than Ki-67 for evaluation of dysplastic oral lesions: an immunohistochemical study. J Oral Pathol Med 43:427–434. https://doi.org/10.1111/jop.12153CrossRefPubMed

32.

Li HT, Wei B, Li ZQ, Wang X, Jia WX, Xu YZ, Liu JY, Shao MN, Chen SX, Mo NF, Zhao D, Zuo WP, Qin J, Li P, Zhang QL, Yang XL (2020) Diagnostic and prognostic value of MCM3 and its interacting proteins in hepatocellular carcinoma. Oncol Lett 20:308. https://doi.org/10.3892/ol.2020.12171CrossRefPubMedPubMedCentral

33.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlén M, Jirström K (2012) High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol 7:82. https://doi.org/10.1186/1746-1596-7-82CrossRefPubMedPubMedCentral

34.

Raja R, Shetty DC, Chandrakanta JS, Tandon A, Gulati N (2021) MCM3 proliferative index is worthier over Ki-67 in the characterization of salivary gland tumors. Indian J Pathol Microbiol 64:22–27. https://doi.org/10.4103/ijpm.Ijpm_63_20CrossRefPubMed

35.

Nowinska K, Chmielewska M, Piotrowska A, Pula B, Pastuszewski W, Krecicki T, Podhorska-Okołow M, Zabel M, Dziegiel P (2016) Correlation between levels of expression of minichromosome maintenance proteins, Ki-67 proliferation antigen and metallothionein I/II in laryngeal squamous cell cancer. Int J Oncol 48:635–645. https://doi.org/10.3892/ijo.2015.3273CrossRefPubMed

36.

Jankowska-Konsur A, Kobierzycki C, Reich A, Grzegrzolka J, Maj J, Dziegiel P (2015) Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. Anticancer Res 35:6017–6026PubMed

37.

MacCallum DE, Hall PA (2000) The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 190:537–544. https://doi.org/10.1002/(sici)1096-9896(200004)190:5%3c537::Aid-path577%3e3.0.Co;2-wCrossRefPubMed

38.

Doger FK, Dikicioglu E, Ergin F, Unal E, Sendur N, Uslu M (2007) Nature of cell kinetics in psoriatic epidermis. J Cutan Pathol 34:257–263. https://doi.org/10.1111/j.1600-0560.2006.00719.xCrossRefPubMed

39.

Madine MA, Swietlik M, Pelizon C, Romanowski P, Mills AD, Laskey RA (2000) The roles of the MCM, ORC, and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struct Biol 129:198–210. https://doi.org/10.1006/jsbi.2000.4218CrossRefPubMed

40.

Lee YS, Ha SA, Kim HJ, Shin SM, Kim HK, Kim S, Kang CS, Lee KY, Hong OK, Lee SH, Kwon HS, Cha BY, Kim JW (2010) Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol 88:138–142. https://doi.org/10.1016/j.yexmp.2009.09.015CrossRefPubMed

41.

Lee LH, Yang H, Bigras G (2014) Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases. Sci Rep 4:5122. https://doi.org/10.1038/srep05122CrossRefPubMedPubMedCentral

42.

Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Giunchi DC, Vio A, Saragoni A, Silvestrini R (1997) Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43:7–14. https://doi.org/10.1023/a:1005780107879CrossRefPubMed

43.

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Polo SH, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, de Fazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Mina F, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J, Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M (2018) Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res 4:250–261. https://doi.org/10.1002/cjp2.109CrossRefPubMedPubMedCentral

44.

Gorski JW, Ueland FR, Kolesar JM (2020) CCNE1 Amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer. Diagnostics (Basel) 10. https://doi.org/10.3390/diagnostics10050279

Titel: MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
verfasst von: Eun Young Kang
Joshua Millstein
Gordana Popovic
Nicola S. Meagher
Adelyn Bolithon
Aline Talhouk
Derek S. Chiu
Michael S. Anglesio
Betty Leung
Katrina Tang
Neil Lambie
Marina Pavanello
Annalyn Da-anoy
Diether Lambrechts
Liselore Loverix
Siel Olbrecht
Christiani Bisinotto
Jesus Garcia-Donas
Sergio Ruiz-Llorente
Monica Yagüe-Fernandez
Robert P. Edwards
Esther Elishaev
Alexander Olawaiye
Sarah Taylor
Beyhan Ataseven
Andreas du Bois
Philipp Harter
Jenny Lester
Claus K. Høgdall
Sebastian M. Armasu
Yajue Huang
Robert A. Vierkant
Chen Wang
Stacey J. Winham
Sabine Heublein
Felix K. F. Kommoss
Daniel W. Cramer
Naoko Sasamoto
Lilian van-Wagensveld
Maria Lycke
Constantina Mateoiu
Janine Joseph
Malcolm C. Pike
Kunle Odunsi
Chiu-Chen Tseng
Celeste L. Pearce
Sanela Bilic
Thomas P. Conrads
Arndt Hartmann
Alexander Hein
Michael E. Jones
Yee Leung
Matthias W. Beckmann
Matthias Ruebner
Minouk J. Schoemaker
Kathryn L. Terry
Mona A. El-Bahrawy
Penny Coulson
John L. Etter
Katherine LaVigne-Mager
Juergen Andress
Marcel Grube
Anna Fischer
Nina Neudeck
Greg Robertson
Rhonda Farrell
Ellen Barlow
Carmel Quinn
Anusha Hettiaratchi
Yovanni Casablanca
Ramona Erber
Colin J. R. Stewart
Adeline Tan
Yu Yu
Jessica Boros
Alison H. Brand
Paul R. Harnett
Catherine J. Kennedy
Nikilyn Nevins
Terry Morgan
Peter A. Fasching
Ignace Vergote
Anthony J. Swerdlow
Francisco J. Candido dos Reis
G. Larry Maxwell
Susan L. Neuhausen
Arantzazu Barquin-Garcia
Francesmary Modugno
Kirsten B. Moysich
Philip J. Crowe
Akira Hirasawa
Florian Heitz
Beth Y. Karlan
Ellen L. Goode
Peter Sinn
Hugo M. Horlings
Estrid Høgdall
Karin Sundfeldt
Stefan Kommoss
Annette Staebler
Anna H. Wu
Paul A. Cohen
Anna DeFazio
Cheng-Han Lee
Helen Steed
Nhu D. Le
Simon A. Gayther
Kate Lawrenson
Paul D. P. Pharoah
Gottfried Konecny
Linda S. Cook
Susan J. Ramus
Linda E. Kelemen
Martin Köbel
Publikationsdatum: 15.11.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 4/2022
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-021-03232-0

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

NUT carcinoma of the parotid gland: report of two cases, one with a rare ZNF532-NUTM1 fusion

CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer

Gene expression profiling using targeted RNA-sequencing to elucidate the progression from histologically normal lung tissues to non-invasive lesions in invasive lung adenocarcinoma

Spindle cell/sclerosing rhabdomyosarcoma with DCTN1::ALK fusion: broadening the molecular spectrum with potential therapeutic implications

Low level of interobserver concordance in assessing histological subtype and tumor grade in patients with penile cancer may impair patient care

Desmoplastic reactions and epithelial-mesenchymal transition proteins in stages II and III colorectal cancer: association with and prognostic value for disease-free survival

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien